PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its activity at MC3R and MC4R, two G-protein-coupled receptors concentrated in the hypothalamus and limbic system. This guide covers the PT-141 peptide's receptor pharmacology, what the published clinical-pharmacology literature reports about its tolerability profile, and the purity standards researchers should expect from any research-grade PT-141 peptide source.
What the PT-141 Peptide Actually Is
PT-141 is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) derived from alpha-melanocyte-stimulating hormone (α-MSH) through cyclization and targeted amino acid substitution. Those modifications were originally introduced to improve proteolytic stability relative to native α-MSH, and the resulting analog is structurally related to Melanotan II, from which it was first isolated as a metabolite during early melanocortin research programs.
Researchers sourcing the PT-141 peptide for in vitro or preclinical work will find it listed by either name — PT-141 or bremelanotide — interchangeably in the literature. Both refer to the same amino acid sequence. In8 Longevity Peptides carries PT-141 (Bremelanotide) in our research-grade catalog, produced to the same identity and purity standard as the other melanocortin-family compounds we supply.
Why MC3R and MC4R Are the Center of PT-141 Research
Unlike Melanotan I and Melanotan II, which act broadly across melanocortin receptor subtypes including the peripherally expressed MC1R that drives pigmentation, PT-141 research has focused on its activity at MC3R and MC4R — the subtypes most densely expressed in the hypothalamic and limbic regions of the central nervous system rather than in skin. Both receptors are Gs-coupled: ligand binding activates adenylyl cyclase, raises intracellular cAMP, and — in neuronal tissue — triggers secondary activation of phospholipase C (PLC) and the ERK/MAPK cascade.
MC4R knockout models have been particularly informative for this line of research. Male knockout mice show markedly impaired erectile function, and females show reduced sexual receptivity, which is how MC4R was first isolated as a mediator of centrally-regulated arousal circuitry rather than a peripheral vascular one. That distinction — a centrally acting melanocortin pathway as opposed to the peripheral, nitric-oxide-driven pathway that PDE5 inhibitors target — is the reason PT-141 shows up in comparative pharmacology studies alongside vascular-acting compounds: the two mechanisms are pharmacologically independent, which is itself a useful property for researchers designing combination or comparison protocols.
The CNS Circuitry Downstream of Receptor Activation
Published pharmacology work describes the downstream circuit as converging on the medial preoptic area, with dopaminergic, oxytocinergic, and noradrenergic signaling systems all implicated in propagating the MC4R signal into behavioral and physiological endpoints. This is one of the more mechanistically mapped melanocortin pathways in the literature, which is part of why PT-141 continues to appear in receptor-pharmacology and CNS-signaling research years after the initial isolation work — researchers have a relatively well-characterized signaling cascade to build time-course and dose-response study designs around.
Clinical-pharmacology trials — conducted under FDA oversight as part of the drug-development program that eventually produced the prescription therapeutic Vyleesi (bremelanotide), approved in 2019 for a specific indication in premenopausal women — generated a substantial published record on PT-141's pharmacokinetics and receptor-binding behavior at defined doses. It's worth being precise about what that history means for a research compound: Vyleesi is a distinct, FDA-regulated pharmaceutical product manufactured under cGMP conditions for prescription use. The PT-141 peptide available through research-chemical suppliers, including the batch in our own catalog, is sold strictly for laboratory and in vitro research — it is not Vyleesi, is not interchangeable with it, and researchers should not treat the existence of an approved drug analog as a safety or legality statement about an unapproved research compound. What the trial literature does provide is a well-documented pharmacokinetic and receptor-binding dataset that's useful as a reference point for in vitro assay design and time-course planning.
Designing a PT-141 Research Protocol: What the Literature Signals for Study Parameters
Because PT-141's receptor pharmacology has been mapped across multiple published pharmacokinetic studies, researchers designing new protocols have real precedent to draw from — not for administration guidance, but for study-design parameters like sampling windows and endpoint selection. Published pharmacokinetic work has reported plasma concentration curves following controlled administration, with peak concentrations occurring within roughly 30–60 minutes and a terminal half-life in the range documented across the intranasal and subcutaneous PK studies cited below. For researchers building in vitro receptor-binding assays or ex vivo tissue studies, that PK profile is a useful reference for selecting sampling intervals across a time-course — early points to capture the absorption phase, and later points spanning the reported elimination half-life.
Dose-response characterization in the original clinical-pharmacology trials used a multi-arm design across a defined dose range, which is the kind of structure worth mirroring in any new preclinical dose-response curve: enough distinct concentration points to resolve an EC50 or comparable potency metric, plus a vehicle-only control arm. Researchers combining PT-141 with other melanocortin-family compounds in a comparative protocol — MT-1, MT-2, or other MC-receptor ligands — should also budget for a receptor-selectivity control, since PT-141's relative MC3R/MC4R selectivity versus MT-2's broader receptor activity is itself an experimental variable worth isolating.
What the Published Safety and Tolerability Data Report
The clinical-pharmacology literature on PT-141 includes several controlled trials that documented adverse-event rates under supervised, dose-controlled conditions. The most consistently reported findings were flushing and nausea, described as the most common adverse events across the intranasal and subcutaneous PK/PD studies; a separate published analysis specifically evaluated ambulatory blood pressure responses to bremelanotide, given the compound's activity on melanocortin pathways with known links to cardiovascular regulation. That safety literature describes outcomes observed in controlled, prescription-context human trials conducted under regulatory supervision — it does not describe or endorse handling or use of unregulated research material, and it should not be read as safety guidance for laboratory research use.
For research settings, the relevant safety consideration is standard peptide-handling practice: verified identity and purity before use in any assay, appropriate PPE, and storage conditions consistent with the compound's stability profile (lyophilized peptides of this class are generally stored frozen and protected from light prior to reconstitution for research use). Our peptide storage and handling guide covers those baseline lab practices in more detail.
Purity and COA Standards: Why Sourcing Matters More for Melanocortin-Family Peptides
PT-141 shares a research-chemical market with several other melanocortin-pathway peptides — Melanotan I, Melanotan II, and related analogs — that are frequently sold with inconsistent purity documentation. Because these compounds are structurally close cousins, a supplier without rigorous batch-level testing has more room to make an identity error than with a structurally distinct peptide. That's one of the reasons we treat third-party COA verification as non-negotiable for every batch of PT-141 (Bremelanotide) in our catalog: mass spectrometry confirmation of molecular identity, HPLC purity assay, and documentation researchers can cross-reference against the expected structure before it goes anywhere near an assay. Our COA standards guide walks through how to read that documentation and what purity thresholds to look for across our catalog.
Sourcing discipline matters especially when a research design calls for comparing PT-141 against other melanocortin-receptor ligands — if the reference compound and the test compound come from suppliers with different testing rigor, any observed difference in assay results is confounded by an uncontrolled purity variable. Keeping every melanocortin-family compound in a single research protocol sourced from the same COA-verified batch process removes that confound.
PT-141 in Comparative and Combination Research Design
Because PT-141's mechanism (central, MC3R/MC4R-mediated) is pharmacologically distinct from the peripheral, nitric-oxide-dependent pathway studied with PDE5-class compounds, it appears in comparative pharmacology literature as an example of a centrally-acting versus peripherally-acting mechanism pair — useful for researchers studying arousal-circuit pharmacology broadly rather than a single pathway in isolation. It's also grouped with other melanocortin peptides in receptor-selectivity comparison work; our MT-1 vs. MT-2 vs. GHK-Cu comparison covers how the pigmentation-focused melanocortin analogs differ mechanistically from PT-141's more centrally-restricted receptor profile, which is useful background before designing a receptor-selectivity study that spans the melanocortin family. For a broader framework on how researchers structure multi-compound protocols generally — sequencing, control-arm design, and avoiding confounded comparisons — see our peptide stacking and combination protocols guide.
Frequently Asked Questions
Is PT-141 legal to buy for research purposes?
PT-141 (bremelanotide) is legal to purchase in the United States as a research chemical sold strictly for laboratory and in vitro research use, not for human or veterinary use. It is a distinct product category from Vyleesi, the FDA-approved prescription version of the same peptide sequence, which requires a prescription for its approved clinical indication. Researchers should confirm current regulations in their own jurisdiction before ordering, as research-chemical regulations vary by state and country.
What receptors does PT-141 target?
PT-141 is studied primarily as an agonist at MC3R and MC4R, two melanocortin receptor subtypes concentrated in the hypothalamus and limbic system. Both are Gs-coupled receptors that activate adenylyl cyclase and raise intracellular cAMP upon ligand binding, with secondary PLC and ERK/MAPK signaling reported in neuronal tissue.
How does PT-141 compare to Melanotan II mechanistically?
PT-141 was originally identified as a metabolite of Melanotan II and shares its melanocortin-receptor-agonist activity, but the two differ in receptor selectivity. Melanotan II activates melanocortin receptors more broadly, including the peripherally expressed MC1R associated with pigmentation research. PT-141's research profile centers on MC3R/MC4R activity in the central nervous system rather than the peripheral pigmentation pathway.
What does published pharmacokinetic research say about PT-141's half-life?
Controlled clinical-pharmacology trials evaluating intranasal and subcutaneous administration have reported peak plasma concentrations within roughly 30–60 minutes, with a defined terminal elimination half-life documented in the cited PK/PD literature. Researchers designing time-course sampling protocols can use those published parameters as a reference point for assay planning.
What purity standard should a PT-141 research peptide meet?
Research-grade PT-141 should come with third-party certificate of analysis (COA) documentation confirming molecular identity via mass spectrometry and purity via HPLC assay, typically ≥98% for research applications. Given how structurally close PT-141 is to other melanocortin-family peptides, COA verification is especially important for confirming the batch matches the intended sequence.
Cited Research Literature
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic peptide melanocortin receptor agonist and erectile response. PubMed PMID 14963471
- Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of intranasal PT-141. PubMed PMID 14999221
- Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). PubMed PMID 16839319
- Rosen RC, Diamond LE, Earle DC, et al. Co-administration of low doses of intranasal PT-141 and sildenafil. PubMed PMID 15833522
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. PubMed PMID 27977473
- King SH, Mayorov AV, Balse-Srinivasan P, et al. Melanocortin receptors, melanotropic peptides and penile erection. PubMed PMID 12851303
Sourcing PT-141 for Research
PT-141 (Bremelanotide) is available in our research-grade catalog, produced with the same COA-verified purity standard as every melanocortin and recovery-research peptide we carry. If your protocol involves comparing PT-141 against other melanocortin ligands, our catalog also includes MT-1 (Melanotan 1) for receptor-selectivity comparison work. Browse our research catalog →
All products are sold strictly for laboratory and in vitro research use only, and are not intended for human or veterinary use, diagnostic procedures, or any application outside a qualified research setting.